Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥60 years old.

American journal of hematology - 1 Jul 2015

Gupta Neha, Miller Austin, Gandhi Shipra, Ford Laurie A, Vigil Carlos E, Griffiths Elizabeth A, Thompson James E, Wetzler Meir, Wang Eunice S

Abstract excerpt

Older patients with acute myeloid leukemia (AML) have poor outcomes with standard induction chemotherapy. We retrospectively reviewed our institute's experience with epigenetic (Epi) versus cytarabine- and anthracycline-based intensive chemotherapy (IC) as induction in newly diagnosed AML patients aged 60 years and older. One hundred sixty-seven patients (n = 84, IC; n = 83, Epi) were assessed; 69 patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Azacitidine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytarabine

Share to Decitabine

Share to Induction Chemotherapy

Share to Leukocyte Count

Share to Nucleophosmin

Share to Remission Induction

Source

Open in PubMed Open full text

Identifiers

PMID: 25808347
DOI: 10.1002/ajh.24016
PMCID: PMC6791130

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥60 years old.PMID 25808347Read ↗

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.Semantic proximity Read ↗

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional careSemantic proximity Read ↗

Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.Semantic proximity Read ↗

Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia.Semantic proximity Read ↗

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.Semantic proximity Read ↗

Long-term remission and survival in older adults with IDH-mutated acute myeloid leukemia treated with IDH inhibitors.Semantic proximity Read ↗

Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid LeukemiaSemantic proximity Read ↗

AML in the Elderly - When less may be more.Semantic proximity Read ↗

Genetic alterations and their clinical implications in older patients with acute myeloid leukemia.Semantic proximity Read ↗

Modified Azacitidine plus Cytarabine versus Traditional Cytarabine in Patients with Newly Diagnosed Acute Myeloid Leukemia: A Retrospective and Propensity Score Matched AnalysisSemantic proximity Read ↗

Clinical Results of Hypomethylating Agents in AML TreatmentSemantic proximity Read ↗

Phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in older patients with newly diagnosed acute myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.